{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["80(5)"],"submitter":["Van Den Berg S"],"funding":["the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)","ZonMw","the Joint Programming Initiative on Antimicrobial Resistance"],"pubmed_abstract":["Background
Antibiotic combination therapy is increasingly used to treat MDR pathogens. In vitro studies suggest that the polymyxin B/rifampicin combination might be synergistic. Therefore, the pharmacodynamics of rifampicin as monotherapy and combined with polymyxin B were studied in Escherichia coli- and Klebsiella pneumoniae-infected mice.Methods
The rifampicin pharmacokinetics (oral doses 0.5-64 mg/kg) in murine plasma were studied to estimate the exposures to rifampicin. These exposures were subsequently correlated with the antibacterial effect in a sigmoid maximum-effect model. The minimum exposures needed for a static, 1 log10 and 2 log10 kill effect in two E. coli and two K. pneumoniae strains were determined for monotherapy and the combination. The pharmacodynamic i"],"journal":["The Journal of antimicrobial chemotherapy"],"pagination":["1248-1255"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12046403"],"repository":["biostudies-literature"],"pubmed_title":["The synergistic effect of the combination of polymyxin B and rifampicin in a murine neutropenic thigh infection model with E. coli and K. pneumoniae."],"pmcid":["PMC12046403"],"pubmed_authors":["Marchand S","Ten Kate MT","Muller AE","Sassen SDT","Couet W","Meletiadis J","Van Den Berg S","Van Der Spek H"],"additional_accession":[]},"is_claimable":false,"name":"The synergistic effect of the combination of polymyxin B and rifampicin in a murine neutropenic thigh infection model with E. coli and K. pneumoniae.","description":"Background
Antibiotic combination therapy is increasingly used to treat MDR pathogens. In vitro studies suggest that the polymyxin B/rifampicin combination might be synergistic. Therefore, the pharmacodynamics of rifampicin as monotherapy and combined with polymyxin B were studied in Escherichia coli- and Klebsiella pneumoniae-infected mice.Methods
The rifampicin pharmacokinetics (oral doses 0.5-64 mg/kg) in murine plasma were studied to estimate the exposures to rifampicin. These exposures were subsequently correlated with the antibacterial effect in a sigmoid maximum-effect model. The minimum exposures needed for a static, 1 log10 and 2 log10 kill effect in two E. coli and two K. pneumoniae strains were determined for monotherapy and the combination. The pharmacodynamic i","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2025-07-08T03:10:56.559Z","creation":"2025-07-08T03:10:56.559Z"},"accession":"S-EPMC12046403","cross_references":{"pubmed":["40036260"],"doi":["10.1093/jac/dkaf056"]}}